51 studies found for:    Open Studies | "Cytomegalovirus Infections"
Show Display Options
Rank Status Study
21 Recruiting Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Conditions: CMV Infection;   Persistent CMV Viremia
Intervention: Genetic: CMVpp65 Specific T-cells
22 Not yet recruiting Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection
Condition: Cytomegalovirus Infections
Intervention: Biological: IFN-γ positive selected T-cells
23 Recruiting Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis
Condition: Cytomegalovirus Infections
Intervention: Drug: 2% guttae ganciclovir
24 Recruiting Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy
Condition: Congenital Cytomegalovirus Infection
Interventions: Drug: Valacyclovir;   Drug: Placebo
25 Recruiting Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients
Conditions: Cytomegalovirus Infection;   GVHD
Intervention:
26 Recruiting A Cohort Study of Cytomegalovirus(CMV) Infection Among Pregnant Women and Their Newborns in China
Conditions: Congenital Cytomegalovirus Infection;   Cytomegalovirus Infection Reactivation
Intervention:
27 Recruiting A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Conditions: Congenital Cytomegalovirus Infection;   Maternal Cytomegalovirus Infection
Intervention: Drug: CMV hyperimmune globulin
28 Recruiting Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients
Condition: Cytomegalovirus Disease
Interventions: Other: Preemptive Therapy;   Drug: Prophylaxis with Valganciclovir
29 Recruiting Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit
Condition: Congenital CMV Infection
Intervention: Other: Education of parents to pursue prompt hearing screening.
30 Recruiting Immunological Characteristics of Maternal-fetal Transmission of Cytomegalovirus in Pregnancy
Conditions: Pregnancy;   Cytomegalovirus Infections;   Congenital Infection
Intervention:
31 Recruiting Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
Conditions: Sensorineural Hearing Loss;   Cytomegalovirus Infection
Intervention:
32 Not yet recruiting Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients
Condition: Cytomegalovirus Viraemia
Intervention: Other: Quantiferon-CMV assay
33 Not yet recruiting Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance
Condition: Congenital Cytomegalovirus (CMV)
Intervention: Drug: Valganciclovir
34 Recruiting Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Condition: Cytomegalovirus
Intervention: Genetic: CMV-pp65 CTLs
35 Recruiting Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
Conditions: Congenital Cytomegalovirus Infection;   Sensorineural Hearing Loss
Intervention: Drug: Valganciclovir
36 Recruiting Biochip for HCMV Detection in Breast Milk
Conditions: Cytomegalovirus Infections;   Breast Feeding;   Premature Birth of Newborn
Intervention:
37 Recruiting Administration of Virus Specific CTLs for the Prophylaxis and Treatment of EBV/CMV Infections After HSCT in China
Condition: Viral Infection
Intervention: Biological: CMV/EBV specific CTLs
38 Recruiting Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant
Conditions: CMV Infection;   Kidney Transplantation
Intervention: Other: BIOMARKER- elispot test
39 Recruiting Congenital CMV and Hearing Loss in Children up to 4 Years of Age: Treating With Valganciclovir Therapy
Conditions: Congenital Cytomegalovirus;   Hearing Loss
Interventions: Drug: Valcyte (Valganciclovir hydrochloride) Powder for oral solution;   Drug: Placebo
40 Recruiting Assessment of CMV-specific ELISPOT Assay for Predicting CMV Colitis in Patient With Ulcerative Colitis
Conditions: Ulcerative Colitis;   Cytomegalovirus Infections;   Disease Exacerbation
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-51) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.